Lly stock forecast eli Lilly’s R&D spend at $9

Eli Lilly’s R&D spend at $9.65B annually supports the LLY stock forecast calling for multiple drug launches by The weight-loss drug market has exploded into one of the fastest-growing markets in recent years. Novo Nordisk (NVO) has cemented itself as the leader in the booming weight-loss drug market with blockbuster treatments like Wegovy and Ozempic. However, Eli Lilly (LLY), armed with fast-rising competitors Mounjaro and Zepbound, is mounting a serious challenge. As both companies race to capture a market projected to be worth $381.5 billion by 2033, the battle for dominance is intensifying. Let’s find out whether Novo’s lead is truly secure. Regarding cardiology, I have highlighted beginning in 2024 a new class of medications, the Lp(a) inhibitors. Lp(a) is an independent risk factor for cardiovascular disease, and it is estimated that 20% of the global population has a level above 50 mg/dL . In the U.S., about 64 million Americans have a high Lp(a) and that 19 million have ASCVD (atherosclerotic cardiovascular disease). Despite the prevalence, testing is rarely done, primarily due to the lack of a pharmacotherapy. However, with several promising therapies now in development (see below), the guideline landscape is changing. The AHA, the ACC, the American Association of Clinical Endocrinology, and the American College of Endocrinology suggest that adults with a family or personal history of premature ASCVD would benefit from Lp(a) testing. However, the latest NLA scientific statement (published in early 2024), the EAS, and the Canadian Cardiovascular Society recommend measuring Lp(a) levels at least once in all adults to refine ASCVD risk. The NLA additionally recommends Lp(a) testing in pediatric patients (< 18 years of age) with suspected or confirmed familial hypercholesterolemia, a family history of premature ASCVD, an unknown cause of ischemic stroke, and/or a parent or sibling with elevated Lp(a) levels . Current LLY stock forecast analysis shows volatility is trending lower, a bullish sign for long-term holders. Hedge fund ownership has climbed 12% this quarter, betting on Eli Lilly’s dominance in metabolic disease therapies. Price action suggests consolidation in the $800–$820 range before another rally leg.